Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross-sectional study.

Sigal KaplanOliver PatinoCarolyn RainvilleTerri Madison

Published in: Pharmacoepidemiology and drug safety (2019)

HCPs and patients/caregivers have good knowledge about the common side effects associated with CMS. However, knowledge of correct use of the Turbospin inhaler and capsule breakage was moderate to low.

Keyphrases

end stage renal disease
healthcare
newly diagnosed
chronic kidney disease
peritoneal dialysis
palliative care
prognostic factors
physical activity
patient reported outcomes
risk factors